In cellular system’s engineering, the lab engineers the secretory system of eukaryotic cells, for the production of challenging biomedical target proteins. This resulted in the GlycoSwitch glycan humanization system in Pichia pastoris. We are developing Pichia as a platform to rapidly produce antibodies to respond to epidemics. Based on our antibody and protein engineering experience, together with colleague Xavier Saelens, we were able to rapidly convert an anti-SARS nanobody into an anti-SARS-CoV-2 VHH-Fc therapeutic lead candidate (Cell, 2020). More recent work deals with protein secretability assessment at proteome-wide level and with glyco-engineering of mammalian cells. In the bioanalytical field, we develop novel methods for the analysis of protein-linked glycans with mass spectrometry and capillary electrophoresis on DNA sequencers, and for the analysis of DNA methylation modifications. Both dynamic modifications reflect tissue (patho)physiology and contain valuable diagnostic information. In 2016, the patents related to glycomics-based liver disease biomarkers were licensed to Helena Biosciences Europe.